Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.» Read More
Pete Najarian reveals 3 biotechs he feels provide the most bang for the buck?
Our traders are good - but you knew that! Check out their latest picks that paid.
Following are the day’s biggest winners and losers. Find out why shares of AIG and Biogen popped while Hasbro and CME Group dropped.
The buyout offer from Swiss drug giant Roche has shares of DNA trading at their highest level in about two-and-a-half years and according to CNBC stock-stat maven, Robert Hum, if they close up at least 8.88% it'll be their biggest one-day percentage gain since April 15, 2005.
You’ve gotta’ love modern medicine. Not only does it cure stomach upset now it may be the best remedy for what ails your portfolio.
The Dow rose Tuesday in another turbulent session after a pullback in oil prices eased worries about consumer and business spending. What's the "Word on the Street?"
As much as I tried to disconnect during my vacation last week, I couldn't escape the ubiquitous presence of pharmaceuticals in our everyday lives...
Corporate raider Carl Icahn has had much to say about Yahoo's internal machinations and its refusal to submit to the hostile overtures of Microsoft. He's had much to say about the company's planned partnership with Google, which surprisingly, seemed a little more positive than many experts had anticipated.
High oil prices and a wary skittishness among traders keeps the pressure on stocks going into Thursday's session. Weekly jobless data, reported at 8:30am ET, is the big number ahead of Thursday's bell. The Philadelphia Fed survey and leading indicators are released at 10am.
High oil prices and a wary skittishness among traders keeps the pressure on stocks going into Thursday's session.
Now we bring you even more Fast ways to trade tomorrow's market moving events. Also Jon Najarian's options action trade!
ISS recommends a vote against dissident slate and looks ahead to CSX' shareholder meeting.
With the ASCO conference beginning Friday new cancer drugs are likely to grab headlines. How should you trade ahead of biotech’s biggest weekend?
So, Carl Icahn is grabbing headlines this week over his new battle with Yahoo and how Boone Pickens is backing him up now, too. But Icahn has his finger in a lot of pies. He's still in a proxy fight with Biogen Idec where he's trying to get his people on the Board at the upcoming shareholder meeting on June 19th.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
Stocks closed mixed in thin trading Tuesday as the tide turned in technology's favor. Airline stocks rose as oil prices receded. Merck skidded after an FDA rejection.
Stocks pushed higher Tuesday despite concerns about interest rates ahead of the Federal Reserve's decision. Merck skidded after an FDA rejection. Airline stocks rose as oil prices receded.
Stocks declined Tuesday amid concerns about interest rates and a slide in consumer confidence. Merck dragged on the Dow industrials after the FDA rejected a key cholesterol drug.
Genentech and Biogen Idec said a key study of Rituxan did not meet its main goal of a response in patients with systemic lupus erythematosus, commonly called lupus.
Investors are finding no solace in Merck's reaffirmation that it'll still hit its earnings numbers this year. Instead they're punishing the stock after the company announced what everyone is calling a surprise and a significant setback.